Published Date:2021-03-23 Original Link:https://www.onenessbio.com/en/news_detail31_4.htm No 1 Date of announcement  2021/03/23 Time of announcement 18:17:00 Subject Oneness Biotech Co.,LTD receives a Taiwan patent on antagonistic PDL1 aptamers.      To which item it meets paragraph 53 Date of events  2021/03/23 Statement      1.Date of occurrence of the event:2021/03/23 2.Company name:ONENESS BIOTECH CO., LTD. 3.Relationship to...Read More

Published Date:2021-03-13 Original Link:https://www.onenessbio.com/en/news_detail30_4.htm No 1 Date of announcement   2021/03/13 Time of announcement  20:52:32 Subject Oneness has been notified by Microbio Shanghai Co., Ltd. that CDE under NMPA accepted NDA application by writing for, the DFU new drug: ON101      To which item it meets paragraph 10 Date of events  2021/03/13 Statement 1.Product:ON101 Diabetic...Read More

Published Date:2021-03-13 Original Link:https://www.onenessbio.com/en/news_detail29_4.htm No 1 Date of announcement   2021/03/13 Time of announcement  17:05:18 Subject Oneness has been notified that FB704A, a fully-human anti-IL6 antibody new drug, is safe to proceed with the phase 2 clinical trial in severe asthma under US FDA IND      To which item it meets paragraph 10 Date of...Read More

Published Date:2021-02-24 Original Link:https://www.onenessbio.com/en/news_detail28_4.htm No 1 Date of announcement   2021/02/24 Time of announcement  08:42:18 Subject Oneness received the letter from MOHW informing that ON101 for DFUs has obtained the new drug approval and its drug certificate will be notified for receipt.      To which item it meets paragraph 10 Date of events  2021/02/24 Statement...Read More

Published Date:2021-02-15 Original Link:https://www.onenessbio.com/en/news_detail27_4.htm No 1 Date of announcement   2021/02/15 Time of announcement  08:42:18 Subject Oneness submits an IND to US FDA on a phase II clinical trial on severe asthma of FB704A, a mAb developed from its own platform.      To which item it meets paragraph 10 Date of events  2021/02/13 Statement 1.Product:FB704A...Read More

Published Date:2021-02-09 Original Link:https://www.onenessbio.com/en/news_detail26_4.htm No 1 Date of announcement  2021/02/09 Time of announcement  17:10:57 Subject Oneness will not proceed with the ON101 Phase3 clinical trial (ON101CLCT04) application with BfArM of Germany based on strategic consideration.      To which item it meets paragraph 10 Date of events 2021/02/09 Statement 1.Product:ON101 2.Mass production date:NA 3.Effect on...Read More

Published Date:2021-02-02 Original Link:https://www.onenessbio.com/en/news_detail25_4.htm No 1 Date of announcement 2021/02/02 Time of announcement  21:33:43 Subject Oneness Biotech Co.,LTD receives a U.S. patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on the developing new drug: ON101 Cream.      To which item it meets paragraph 53 Date of events 2021/02/02 Statement 1.Date of occurrence of the...Read More

Published Date:2021-01-29 Original Link:https://www.onenessbio.com/en/news_detail24_4.htm No 2 Date of announcement  2021/01/29 Time of announcement        18:56:05 Subject Oneness Biotech Co.,LTD receives a European patent on antagonistic PDL1 aptamers.      To which item it meets paragraph 53 Date of events       2021/01/29 Statement 1.Date of occurrence of the event:2021/01/29 2.Company name:ONENESS BIOTECH CO., LTD....Read More

Published Date:2021-01-29 Original Link:https://www.onenessbio.com/en/news_detail23_4.htm No 1 Date of announcement  2021/01/29 Time of announcement       18:54:40 Subject Oneness Biotech Co.,LTD receives a European patent on antagonistic CTLA-4 aptamers.      To which item it meets paragraph 53 Date of events       2021/01/29 Statement 1.Date of occurrence of the event:2021/01/29 2.Company name:ONENESS BIOTECH CO., LTD....Read More

Published Date:2021-01-14 Original Link:https://www.onenessbio.com/en/news_detail22_4.htm No 1 Date of announcement   2021/01/14 Time of announcement  17:17:29 Subject Oneness announces that LEO PHARMA made the 2nd upfront payment of US$15.12MM according to the agreement. A total of US$33.6MM upfront payments have been received.       To which item it meets paragraph 53 Date of events     ...Read More